Saporito Gennaro, Sucapane Patrizia, Bruno Federico, Catalucci Alessia, Masciocchi Carlo, Pistoia Maria Letizia, Splendiani Alessandra, Ricci Alessandro, Di Cesare Ernesto, Marini Carmine, Mazza Monica, Totaro Rocco, Pistoia Francesca
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Department of Neurology, San Salvatore Hospital, L'Aquila, Italy.
Front Neurol. 2024 Jun 17;15:1395282. doi: 10.3389/fneur.2024.1395282. eCollection 2024.
In the COGNitive in Focused UltraSound (COGNIFUS) study, we examined the 6-month cognitive outcomes of patients undergoing MRgFUS thalamotomy. This study endorsed the safety profile of the procedure in terms of cognitive functions that cannot be evaluated in real-time during the procedure unlike other aspects. The aim of the COGNIFUS Part 2 study was to investigate the cognitive trajectory of MRgFUS patients over a 1-year period, in order to confirm long-term safety and satisfaction.
We prospectively evaluated the cognitive and neurobehavioral profile of patients with essential tremor (ET) or Parkinson's Disease (PD) related tremor undergoing MRgFUS thalamotomy at 1 year-follow-up following the treatment.
The sample consists of 50 patients (male 76%; mean age ± SD 69.0 ± 8.56; mean disease duration ± SD 12.13 ± 12.59; ET 28, PD 22 patients). A significant improvement was detected at the 1 year-follow-up assessment in anxiety and mood feelings (Hamilton Anxiety rating scale 5.66 ± 5.02 vs. 2.69 ± 3.76, ≤ <0.001; Beck depression Inventory II score 3.74 ± 3.80 vs. 1.80 ± 2.78, = 0.001), memory domains (Rey Auditory Verbal Learning Test, immediate recall 31.76 ± 7.60 vs. 35.38 ± 7.72, = 0.001 and delayed recall scores 5.57 ± 2 0.75 vs. 6.41 ± 2.48), frontal functions (Frontal Assessment Battery score 14.24 ± 3.04 vs. 15.16 ± 2.74) and in quality of life (Quality of life in Essential Tremor Questionnaire 35.00 ± 12.08 vs. 9.03 ± 10.64, ≤ 0.001 and PD Questionnaire -8 7.86 ± 3.10 vs. 3.09 ± 2.29, ≤ 0.001).
Our study supports the long-term efficacy and cognitive safety of MRgFUS treatment for ET and PD.
在聚焦超声认知（COGNIFUS）研究中，我们研究了接受磁共振引导聚焦超声丘脑切开术患者的6个月认知结果。与该手术的其他方面不同，本研究认可了该手术在认知功能方面的安全性，因为在手术过程中无法实时评估认知功能。COGNIFUS第2部分研究的目的是调查磁共振引导聚焦超声（MRgFUS）患者在1年期间的认知轨迹，以确认长期安全性和满意度。
我们前瞻性评估了在治疗后1年随访时接受磁共振引导聚焦超声丘脑切开术的特发性震颤（ET）或帕金森病（PD）相关震颤患者的认知和神经行为特征。
样本包括50名患者（男性占76%；平均年龄±标准差为69.0±8.56；平均病程±标准差为12.13±12.59；ET患者28例，PD患者22例）。在1年随访评估中，焦虑和情绪感受（汉密尔顿焦虑量表评分5.66±5.02 vs. 2.69±3.76，P≤0.001；贝克抑郁量表II评分3.74±3.80 vs. 1.80±2.78，P = 0.001）、记忆领域（雷伊听觉词语学习测验，即时回忆31.76±7.60 vs. 35.38±7.72，P = 0.001和延迟回忆分数5.57±2.075 vs. 6.41±2.48）、额叶功能（额叶评估量表评分14.24±3.04 vs. 15.16±2.74）以及生活质量（特发性震颤生活质量问卷评分35.00±12.08 vs. 9.03±10.64，P≤0.001和帕金森病问卷-8评分7.86±3.10 vs. 3.09±2.29，P≤0.001）均有显著改善。
我们的研究支持磁共振引导聚焦超声治疗ET和PD的长期疗效和认知安全性。
Zotero 插件
